Perturbation type | Gene | Citation | Cancer type | Gene-disease relation |
---|---|---|---|---|
Top gains | KHDRBS1 (Isoform switch) | 27473117 | Tongue carcinoma | Sam68 (KHDRBS1) reduces cisplatin-induced apoptosis in tongue carcinoma |
Top gains | DLG2 (Isoform switch) | 26949921 | Oropharyngeal squamous cell carcinoma | Differentially expressed in cancer tissue compared to normal controls. |
Top losses | GOSR2 (Isoform switch) | 15170515 | HNSC | Differentially expressed in HNSC patients compared to expression profiles in heathy controls |
Top losses | BCAN (Isoform switch) | 15170515 | HNSC | Differentially expressed in HNSC patients compared to expression profiles in heathy controls |
Top specific gains | HOXC9 | 25860510 | HNSCC | miR-196a and HOXB9 are overexpressed; perhaps coordinately; as HNSCC develops and exert a pro-tumourigenic phenotype in HNSCC and OPM cells. |
Top specific gains | FOXL2 | 16467079 | HNSCC HPV positive | Differentially expressed in HNSCC HPV positive tumor samples compared to HNSCC HPV negative tumor samples. |
Top cancer-specific gains | CEBPE | 16467079 | HNSCC HPV positive | Differentially expressed in HNSCC HPV positive tumor samples compared to HNSCC HPV negative tumor samples. |
Top losses | APP | 15252842 | OSCC | Highly expressed in OSCC. |
Top losses | ASB14 | 16467079 | HNSCC HPV positive | Differentially expressed in HNSCC HPV positive tumor samples compared to HNSCC HPV negative tumor samples. |
Top losses | ASGR1 | 16164832 | OSCC | Down-regulated in metastasizing SCCs of the tongue |
Top losses | AURKC | 16467079 | HNSCC HPV positive | Differentially expressed in HNSCC HPV positive tumor samples compared to HNSCC HPV negative tumor samples. |
Top losses | BMX | 16467079 | HNSCC HPV positive | Differentially expressed in HNSCC HPV positive tumor samples compared to HNSCC HPV negative tumor samples. |
Top losses | CDKL3 | 16467079 | HNSCC HPV positive | Differentially expressed in HNSCC HPV positive tumor samples compared to HNSCC HPV negative tumor samples. |
Top losses | FLT3 | 12536197 | HNSCC | Antitumor effect of secreted Flt3-ligand can act at distant tumor sites in a murine model of head and neck cancer. |
Top losses | GDF9 | 17390032 | HNSCC | Differentially expressed in well-differentiated SCC tumor samples compared to moderately-differentiated SCC tumor samples (HNSC mouse model). |
Top losses | GLIPR1L2 | 30089500 | HNSCC | Differentially expressed in tumor samples compared to normal samples |
Top losses | INCA1 | 30089500 | HNSCC | Differentially expressed in tumor samples compared to normal samples |
Top losses | PCK1 | 16467079 | HNSCC HPV positive | Differentially expressed in HNSCC HPV positive tumor samples compared to HNSCC HPV negative tumor samples. |
Top losses | RXRG | 28823962 | OPSCC | RXRG-methylation(+) significantly associated with better prognosis in HPV-associated OPSCC |
Top losses | TSSK3 | 16467079 | HNSCC HPV positive | Differentially expressed in HNSCC HPV positive tumor samples compared to HNSCC HPV negative tumor samples. |
Top losses | TUBB1 | 24425785 | HNSCC | Paclitaxel (targeting TUBB1) most potently inhibited the growth of HNSCC cell lines. |
Top losses | USP49 | 16467079 | HNSCC HPV positive | Differentially expressed in HNSCC HPV positive tumor samples compared to HNSCC HPV negative tumor samples. |
Top losses | WNK4 | 16467079 | HNSCC HPV positive | Differentially expressed in HNSCC HPV positive tumor samples compared to HNSCC HPV negative tumor samples. |
Top losses | ZNF396 | 16467079 | HNSCC HPV positive | Differentially expressed in HNSCC HPV positive tumor samples compared to HNSCC HPV negative tumor samples. |
Top cancer-specific losses | WNK4 | 16467079 | HNSCC HPV positive | Differentially expressed in HNSCC HPV positive tumor samples compared to HNSCC HPV negative tumor samples. |
SMGs within edgetic gains or losses | AJUBA | 28126323 | HNSCC | Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors. |
SMGs within edgetic gains or losses | CUL3 | 29306329 | HNSCC | KEAP1-NRF2-CUL3 axis which is strongly associated with tumorigenesis and drug resistance in HNSCC. |
SMGs within edgetic gains or losses | EP300 | 23307074 | HNSCC | EP300 is histone acetyltransferase that is mutated in 7% of HNSCC. |
SMGs within edgetic gains or losses | FBXW7 | 26619011 | HNSCC | FBXW7 mutations associated with HNSC. |
SMGs within edgetic gains or losses | HLA-B | 16467079 | HNSCC HPV positive | Differentially expressed in HNSCC HPV positive tumor samples compared to HNSCC HPV negative tumor samples. |
SMGs within edgetic gains or losses | HUWE1 | 28794691 | HNSCC | HUWE1 is a target of lncRNAs described as deregulated in HNSCC. |
SMGs within edgetic gains or losses | TP53 | 27166782 | HNSCC | TP53 mutations are significantly associated with short survival time and tumor resistance to radiotherapy and chemotherapy in HNSCC patients |
To download a file, either filter the gene of interest or select all the entries and then press the "Download as Excel table" button